|Scientific Subdivisions | The Journal of Molecular Diagnostics
Contact AMP | Sign In | Join / Renew | Go To CHAMP
For comments or questions regarding the Open Comment Period, please contact the AMP Office
COMMENT SUBMISSION UPDATE
As of 7/19/2016:
112 individual respondents
3,191 survey responses
572 individual comments
Submit your comments by August 2!
Thank you for your interest in the public open comment period. The current draft recommendations are the product of an Expert Panel charged with reaffirming, updating, and revising the Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors Guideline from the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) published in 2013. [View Paper]
The public open comment period ended on August 2, 2016.
All comments will be returned to the Expert Panel for consideration and evaluation. The open comment format provided an opportunity for public review of both recommendation statements from the 2013 guideline that have been reaffirmed and new draft recommendations developed based upon the systematic literature review. This guideline has been developed consistent with the Institute of Medicine's Clinical Practice Guidelines You Can Trust.
Summary of public comments received will be posted on this website during August 2016.
The CAP/IASLC/AMP Lung Biomarkers Update Expert Panel was convened in 2015 to perform a systematic literature review and develop updated practice guideline recommendations.
The Lung Guideline Update Draft Recommendations and literature search information provided during the open comment period represent time limited information and are not to be distributed, used, or considered as an accurate representation of the CAP/IASLC/AMP Lung Guideline Update Expert Panel work product(s) after August 2, 2016.
Thank you to all who contributed your time and expertise to the Lung Guideline Update Draft Recommendations development process during this open comment period. We look forward to your feedback to further enhance the final recommendations.
Philip T. Cagle, MD on behalf of CAP
Yasushi Yatabe, MD, PhD on behalf of IASLC
Neal Lindeman, MD on behalf of AMP
About the College of American Pathologists (CAP)
As the leading organization of 18,000 board-certified pathologists, the CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP's Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,800 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at cap.org. Follow the CAP on Twitter at @pathologists.
About the International Association for the Study of Lung Cancer (IASLC)
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes more than 5,000 lung cancer specialists in over 100 countries. IASLC members promote the study of etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and thoracic malignancies. IASLC brings scientists, members of the medical community and the public together from all over the world to share best practices and discover new and better ways to eliminate the health threat of thoracic cancers. Membership is open to any physician, scientist, nurse or allied health professional interested in lung cancer and other thoracic malignancies, including patients, survivors, caregivers and advocates. Visit www.iaslc.org for more information and follow us on Twitter @IASLC.
About the Association for Molecular Pathology (AMP)
The Association for Molecular Pathology (AMP) was founded in 1995 to provide structure and leadership to the emerging field of molecular diagnostics. AMP's 2,300+ members include individuals from academic and community medical centers, government, and industry; including pathologist and doctoral scientist laboratory directors; basic and translational scientists; technologists; and trainees. Through the efforts of its Board of Directors, Committees, Working Groups, and members, AMP is the primary resource for expertise, education, and collaboration in one of the fastest growing fields in healthcare. AMP members influence clinical practice, education, and policy on the national and international levels, ultimately serving to advance innovation in the field and protect patient access to high quality, appropriate testing. For more information, visit www.amp.org and follow us on Twitter at @AMPath.